Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 ; volume:6 ; number:5 ; day:25 ; month:8 ; year:2022 ; pages:697-710 ; date:9.2022
PharmacoEconomics - open ; 6, Heft 5 (25.8.2022), 697-710, 9.2022
- Creator
-
Baker, Timothy
Johnson, Helen
Kotapati, Srividya
Moshyk, Andriy
Hamilton, Melissa
Kurt, Murat
Paly, Victoria Federico
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-022-00348-0
- URN
-
urn:nbn:de:101:1-2022112009185930653208
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Baker, Timothy
- Johnson, Helen
- Kotapati, Srividya
- Moshyk, Andriy
- Hamilton, Melissa
- Kurt, Murat
- Paly, Victoria Federico
- SpringerLink (Online service)
Other Objects (12)
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis